Data from the BroADen Phase 1b atopic dermatitis (AD) patient trial expected to be reported in 4Q25Completed SAD/MAD dosing in KT-621 Phase 1 ...

Against the backdrop of Music City’s biggest weekend, leading experts and frontline clinicians will gather in downtown Nashville, Tennessee, for one of dermatology’s most impactful educational events ...

A panelist discusses how real-world data presented at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The FDA approved dupilumab for the treatment of patients 12 years and older with chronic spontaneous urticaria who remain ...

Many people experience an itchy scalp at some point. It’s usually not a sign of a serious medical condition and can, in most ...

For millions of people around the world, asthma is more than just a breathing problem—it is a chronic and often debilitating ...

Dupilumab in atopic dermatitis treatment had the most favorable cardiometabolic safety profile when compared with methotrexate and cyclosporine.

Tralokinumab use in patients with head and neck atopic dermatitis was associated with sustained improvements with up to 4 years of treatment.

Attovia Therapeutics has completed an oversubscribed $90 million Series C financing, which the company plans to use along with existing cash and investments to advance its two lead pipeline candidates ...

Using a topical steroid on your face is a common one, but perioral dermatitis can also show up if you’re using thick or oily skin care products, over-exfoliating, or going through hormonal changes, Dr ...